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Abstract
Purpose Current TNM staging does not appropriately identi-
fy high-risk colorectal cancer (CRC) patients. The aim of this
study was to evaluate whether the presence of disseminated
tumor cells (DTCs) in the bone marrow (BM) and the pres-
ence of stroma in the primary tumor, i.e., the tumor-stroma
ratio (TSR), in patients undergoing surgical resection of pri-
mary CRC provides information relevant for disease outcome.
Methods Patients with primary CRC (n = 125), consecutively
admitted for curative resection between 2001 and 2007, were
included in the study. All patients underwent BM aspiration
before surgery. Detection of tumor cells was performed using
immunocytochemical staining for cytokeratin (CK-ICC). The
TSR was determined on diagnostic H&E stained sections of
primary tumors.
Results DTCs were detected in the BM of 23/125 patients
(18 %). No association was found between BM status and
overall survival (HR 0.97 (95 % CI 0.45–2.09), p = 0.93).
Also, no significant difference was found in their 5-year sur-
vival rate (resp. 72 % and 68 % for BM-positive versus BM-
negative patients). The TSR was found to be associated with a
worse overall survival (HR 2.16, 95%CI 1.02–4.57, p = 0.04)
with 5-year survival rates of 84 % versus 62 % for stroma-low
and stroma-high patients, respectively. No relation was found
between the presence of DTCs and TSR.
Conclusions Our data indicate that the presence of DTCs in
the BM of CRC patients is not associated with disease out-
come. The TSR was, however, found to be associated with a
worse overall survival, which indicates that for CRC the tu-
mor microenvironment plays an important role in its behavior
and prognosis.
Keywords Colon cancer . Disseminated tumor cells . Tumor
microenvironment . Tumor-stroma ratio
1 Introduction
There is a need for predictors of recurrence of disease after
resection of colorectal cancer (CRC) with curative intent. If
tumor recurrence can be identified early enough, potentially
curative reoperations may be considered. Moreover, selective
adjuvant treatment may be administered to patients at a high
risk of recurrence.
In CRC the prognosis and indication for adjuvant therapy is
mainly based on TNM staging. Although this histopathologi-
cal approach is of paramount importance in cancer classifica-
tion, for most CRC patients with stage II disease who are
classified as standard risk, there are no additional markers to
further refine risk assessment or to predict adjuvant chemo-
therapy benefit. On the other hand, subgroups of stage III
CRC patients may not require postoperative adjuvant chemo-
therapy and may, thus, be prevented from chemotherapy tox-
icity and side effects [1]. This implies that current staging does
not appropriately identify all high-risk patients, especially in
the group of lymph node-negative cases (those presumed to
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have localized disease only), of which 25 % does exhibit re-
currence of disease [2].
Available data strongly support the view that disseminated
tumor cells (DTCs) may serve as a candidate biomarker suit-
able for prognostication in (colorectal) cancer [3, 4]. Bone
marrow (BM) appears to be a common homing site for carci-
nomas derived from different organs, and may serve as a res-
ervoir of DTCs with the capacity to metastasize to other dis-
tant organs [4–6]. In breast cancer, for example, the presence
of DTCs is being considered as an independent prognostic
factor for reduced survival [7]. There are several methods to
detect DTCs [8], of which immunocytochemical staining for
cytokeratin (CK-ICC) is the most frequently used and most
standardized technique. Earlier studies have indicated that the
clinical importance of the detection of DCTs in the BM of
CRC patients is still a matter of debate [3, 9].
Before tumor cells become DTCs, they escape from their
microenvironment. Nowadays, there is an increasing appreci-
ation of the importance of the tumor microenvironment, in-
cluding the stromal compartment, in the process of tumorigen-
esis. This compartment facilitates the survival and prolifera-
tion of neoplastic cells and promotes epithelial-mesenchymal
transition (EMT), as well as local and metastatic dissemina-
tion. Moreover, the stroma of each tumor is different in terms
of quantity and cellular composition. In recent years, the tu-
mor stroma has gained interest in the clinic with regard to
patient prognosis and its potential to affect therapy responses.
In colon cancer patients the tumor-stroma ratio (TSR) has
been identified in several studies as an important prognostica-
tor of disease-free and overall survival [10–13].
The aim of this study was to determine the clinical impor-
tance of DTCs in the BM of patients with primary CRC using
immunocytochemical staining for cytokeratin (CK-ICC). We
also compared the CK-ICC data to the TSR data. In addition,




A total of 125 consecutive patients were enrolled in the study
between May 2001 and November 2007. Only patients with
primary CRC (TNM stage I-III) planned for curative resection
in the participating hospitals were included. Patients who died
within 2 months after surgery were excluded. After surgery all
patients underwent routine clinical examination, liver ultraso-
nography and CEA testing. Forty-two patients with stage III
(27/38) or IV (15/18) disease received systemic adjuvant che-
motherapy. Follow-up was carried out in all cases and com-
pleted until June 2014. Approval of the local Medical Ethical
Committees for this study was provided and informed written
consent was obtained from all patients.
2.2 Bone marrow aspirations
From all patients 5–10 ml BM was aspirated from both sides
of the anterior iliac crest under general anesthesia prior to
surgery. Before inserting the needle in the anterior iliac crest,
an incision was made into the overlying skin to prevent con-
tamination with skin epithelial cells. Mononuclear cells were
isolated from the BM by ficoll gradient centrifugation and
aliquoted for the preparation of cytospin-slides for
immunocytochemistry.
2.3 Immunocytochemistry and automated microscopy
The cytospin-slides were stained with primary antibodies di-
rected against cytokeratins 8, 18 and 19 (A45-B/B3;
Micromet AG, Munich, Germany), or with isotype antibodies
directed against an irrelevant antigen as a negative control
(MOPC21; BD Pharmingen, Erembodegem, Belgium). A de-
tailed cytokeratin immunocytochemical (CK-ICC) staining
protocol has been published before by Pantel et al. [14]. CK-
ICC staining results in a red precipitate in the cytoplasm of
cytokeratin-positive cells. The slides were counterstained with
haematoxylin (Mayer’s Hemalaum; Merck, Darmstadt,
Germany) to visualize the nuclei. The slides were analyzed
using an ARIOL SL-50 automated microscope® (Applied
Imaging Corporation, San Jose, CA). One slide stained for
cytokeratin and one negative control slide were analyzed per
patient. Detailed features of this approach have been reported
before [15].
By combining CK-ICC with automated microscopy,
cytokeratin-positive cells were confirmed by an independent
pathologist and categorized into tumor cells, candidate tumor
cells, apoptotic cells or hematopoietic cells, based on morpho-
logical criteria according to the guidelines of the European
ISHAGE Working Group for Standardization of Tumour
Cell Detection [16]. Candidate tumor cells and apoptotic cells
were denoted as cells that did not meet all criteria for a positive
tumor cell, but could not unambiguously be defined as being
normal. A patient was considered positive if at least one tumor
cell, one candidate tumor cell or one apoptotic cell was found.
2.4 Control samples
To validate our technique, we performed CK-ICC staining on
BM derived from 20 breast cancer patients and from 29 indi-
viduals that were operated because of a benign disease without
any evidence of a malignancy until June 2014.
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2.5 Determination of the tumor-stroma ratio
Histopathological examination entailed routine microscopic
analysis of 5 μm H&E stained sections of the primary tumor
as reported before [10]. The slides were selected from themost
invasive part of the tumor (i.e., the slides used in routine pa-
thology to determine the T-status), as indicated in the pathol-
ogy reports, and analyzed by conventional microscopy. In
case the pathology information could not be retrieved, all
available tumor slides were collected and analyzed [10].
Areas with the largest amount of stroma were selected using
a 2.5× or a 5× objective. Areas in which both tumor and
stromal tissue were present were selected using a 10× objec-
tive, after which the final TSR score was determined. Tumor
cells should be present at all borders of the image field(s) to be
selected. Two observers (GvP, WM) estimated the TSR in a
blinded manner. A third independent pathologist was decisive
in case of an inconclusive score or a lack of consensus.
Scoring percentages were given per tenfold (10 %, 20 %,
30 % etc.) per image-field. Since rectal cancer patients are
pre-operatively treated with radiotherapy, which influences
the intra-tumor stroma, only tissues from colon cancer patients
were evaluated for TSR.
2.6 Statistical analyses
Frequencies were described as mean plus standard deviation
(SD), or median plus range in case of a non-normal distribu-
tion. Patients that were found to have synchronous metastases,
defined as metastases found during operation or within
3 months, were excluded from the disease-free survival anal-
yses. The recurrence rate of the patients with a positive CK-
ICC score was compared to those with a negative CK-ICC
score using Cox regression adjusted for sex and age. Hazard
ratios (HRs) were calculated by Cox regression analysis for
overall survival and disease-free survival. Overall survival
was considered from the day of primary tumor surgery to
the day of death or censored at the most recent follow-up date.
Disease-free survival was considered from the day of surgery
to the day of recurrence, or to the day of death, or censored at
the most recent follow-up date. Associations between BM or
TSR status and survival were depicted in Kaplan-Meier sur-
vival curves. Stroma-high was defined as >50 % stroma and
stroma-low as ≤50 % stroma. All analyses were performed
using SPSS for Windows (version 23.0, IBM SPSS Inc,
Chicago, Ill). P-values <0.05 were considered statistically
significant.
3 Results
The study population comprised 125 patients (65 females and
60 males). No complications of BM aspiration were reported.
The patient and tumor characteristics of the study population
are listed in Table 1. The median follow-up time from the date
of diagnosis of the primary tumor was 6.5 years (range: 0–
12 years). Of the 125 patients, 38 developed recurrent disease
during follow-up at either single sites (liver (n = 20), lung (n =
5), peritoneum/lymph node (n = 3), bone (n = 1)), or at multi-
ple sites (n = 9).
3.1 Prevalence of DTCs in BM
In 23 of the 125 patients (18 %) disseminated tumor cells
(DCTs) were found in the BM using CK-ICC. Table 1 shows,
next to the clinical parameters of the patients included in the
study, the percentage of BM-positive patients per TNM stage.
We found that the percentages of BM-positive patients per
stage did not differ significantly. Three patients developed
bone metastases of which two were classified as BM-positive.
The presence of DCTs in the BM was not found to be associ-
ated with TSR (p = 0.28).
3.2 Control groups
In Tables 2 and 3 the patient characteristics of both control
groups are depicted. In 9 of the 20 patients (45 %) operated
because of breast cancer, CK-ICC positive cells were detected
in the BM, whereas in 2 of the 29 patients (7 %) operated
because of benign disease, CK-ICC positive cells were detect-
ed in the BM.
3.3 DTCs and survival
Patients with a CK-ICC negative BM were not found to ex-
hibit a significantly better overall survival (OS) than those
with CK-ICC positive cells in the BM (Fig. 1a); HR 0.97
(95 % CI 0.45–2.09), p = 0.93. No significant difference was
found in the 5 year survival rate of both groups (68 % and
72 %, respectively). Also, the disease-free survival (DFS) did
not show a significant difference between the BM-positive
and BM-negative patient groups (Fig. 1b); HR 0.80
(95 % CI 0.35–1.82), p = 0.59.
3.4 Subgroup analyses
In the lymph node-negative (stage I-II) patients, no significant
difference was observed between the BM-negative and BM-
positive cases in OS or DFS (Fig. 2); HR 0.85 (95 % CI 0.24–
3.04), p = 0.80 and HR 1.83 (95 % CI 0.66–5.09), p = 0.25,
respectively. Also in the group of elderly patients (>70 years),
no significant difference was found between the BM-negative
and BM-positive cases in OS (n = 58; p = 0.25) or DFS (n =
49; p = 0.24). Adjustment for sex, age, tumor location and
chemotherapy did not change the results for any of these sur-
vival analyses.
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3.5 TSR and survival
Five out of 108 pre-selected patients could not be analyzed
due to a poor quality of the histological material and of 6
patients material was not available, leaving H&E sections
from 97 patients for TSR analysis. Fifty-seven of these sec-
tions (59 %) were scored as stroma-low and 40 (41 %) as
stroma-high. Patients with a high stroma percentage within
the primary tumor showed a trend towards a worse OS in an
univariate analysis; HR 1.84 (95 % CI 0.89–3.82), p = 0.10,
with a 5 year survival rate of 84 % versus 62% in those with a
low stroma percentage (Fig. 3). After adjustment for sex, age
and chemotherapy, we found that TSR serves as a prognostic
factor for a worse OS in patients with a high TSR; HR 2.16
(95 % CI 1.02–4.57), p = 0.04. In case of DFS no significant
difference between stroma-low and stroma-high patients was
observed. The 5 year DFS rates were 76 % and 71 % for the
stroma-low and stroma-high cases, respectively.
Table 3 Characteristics of the benign control group
Benign disease N = 28
Sigmoid resection (diverticulitis) 5
Bowel resection (inflammatory bowel disease) 13
Bowel resection (tubulovillous adenoma) 3
Cholecystectomy 4
Benign stenosis duodenum 1
Hernia repair 2
CK-ICC positive 2
Abbreviation: CK-ICC cytokeratin immunocytochemistry
Table 2 Characteristics of the breast cancer control group
Breast cancer patients N = 20






Abbreviation: CK-ICC cytokeratin immunocytochemistry
Table 1 Clinicopathological
characteristics of the study
population
All patients CK-ICC positive CK-ICC negative P value
N = 125 N = 23 N = 102
Gender
Male 60 (48) 15 (65) 45 (44) 0.055
Female 65 (52) 8 (35) 57 (56)
Age (years)a 69 (41–90) 68 (45–79) 69 (41–90) 0.694
Hospital
University 67 (54) 17 (74) 50 (49) 0.025*
Affiliated 58 (46) 6 (26) 52 (51)
Location primary tumor
Colon 108 (87) 18 (78) 90 (88) 0.175
Rectum 17 (13) 5 (22) 12 (12)
TNM stage
I 22 (18) 5 (22) 17 (17) 0.596
II 47 (38) 7 (30) 40 (39)
III 38 (30) 6 (26) 32 (31)
IV 18 (14) 5 (22) 13 (13)
TSRb
Stroma-low 57 (59) 9 (50) 48 (61) 0.282
Stroma-high 40 (41) 9 (50) 31 (39)
Number of LNsa 14 (1–33) 12 (1–20) 14 (1–33) 0.188
Follow-up (years)a 6.5 (0–12) 7.0 (0–12) 5.8 (0–12) 0.851
Death 41 (33) 8 (35) 33 (32) 0.501
Data stated in number (%), unless otherwise indicated
a Stated in median (range)
b Only colon cancer patients evaluated (total N = 97)
Abbreviations: CK-ICC cytokeratin immunocytochemistry, TNM tumor-node-metastasis, TSR tumor-stroma ra-
tio, LNs lymph nodes
540 F.J. Vogelaar et al.
4 Discussion
In nearly one-fifth of the patients with CRC, including early
stage cases, we found DTCs in the BM. These DTCs, detected
by CK-ICC, were not found to impose a significant impact on
the prognosis of patients that underwent resection of the pri-
mary tumor. The idea that a high amount of stroma in the
primary tumor may be related to the presence of DTCs was
not confirmed by our study. We did find, however, that a high
stroma-percentage was associated with a worse overall surviv-
al in the CRC patients included in this study.
Results obtained by others aimed at assessing the prognos-
tic impact of DTCs in primary CRC cases have so far been
conflicting. The amount of positive DTCs in BM were e.g.
found to range from 24 to 64 % [6, 17–22]. These differences
in (mostly) cytokeratin stained cells may reflect the use of
Fig. 2 Kaplan-Meier survival curves for CK-ICC negative and CK-ICC positive patients: overall survival (a) and disease-free survival (b) in lymph
node-negative patients after surgery for primary colorectal cancer
Fig. 1 Kaplan-Meier survival curves for CK-ICC negative and CK-ICC positive patients: overall survival (a) and disease-free survival (b) in patients
after surgery for primary colorectal cancer
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different techniques. Flatmark et al. [23] found that the use of
two different techniques (immunomagnetic selection with an
anti-EpCAM antibody and CK-ICC) resulted in a minimal
detection overlap although, surprisingly, the results of both
methods were found to be associated with disease outcome
in distinct CRC prognostic subgroups. The main conclusion
from their study was that the presence of DTCs in BM may
serve as a prognostic biomarker for curatively resected CRC
patients.
In some studies, the presence of DTCs was found to be
associated with a shorter disease-free survival [18, 24], where-
as in other studies no prognostic relevance of DTCs in the BM
was noted [6, 19, 21]. Steinert et al. [6] detected the same
amount of CK-ICC positive cells throughout all CRC TNM
stages, and Lindemann et al. [18] failed to find a significant
difference between lymph node-positive and -negative pa-
tients, although they did find that the detection of tumor cells
in the BM may serve as an independent determinant of re-
lapse. In both studies immunocytochemistry was used for
BM analysis. Leinung et al. [17] found an increased percent-
age of CK-ICC positive cells in the BM in rectal cancer pa-
tients compared to colon cancer patients. In 2010, Rahbari
et al. published a meta-analysis (in which the above described
studies were also included) to assess whether hematogeneous
DTCs represent a prognostic factor in patients with CRC.
They found a strong prognostic effect of circulating tumor
cells in the peripheral blood but, in accordance with our find-
ings, this effect was not found for DCTs in the BM [25].
A pooled analysis of micro-metastases in the BM of
breast cancer patients [7] revealed that the presence of
DTCs in the BM was predictive for the development of
distant metastases after long term follow-up. Tumor
cell persistence in BM was also found to be an inde-
pendent prognostic factor for subsequent breast cancer
survival [26]. In contrast to breast cancer, in which
bone is one of the most preferential metastatic target
sites affecting more than half of the patients during the
course of their disease, the incidence of bone metasta-
ses in CRC is rare [27, 28]. Three of our 125 patients
developed skeletal metastases during follow-up, two of
which were BM-positive. In 18 % of the patients DTCs
were detected in the BM, but this does not seem to
reflect the presence of skeletal metastases. In our con-
trol group of 20 breast cancer patients, we found in
45 % of the cases DTCs in the BM. This result is in
accordance with other studies reporting DTC occur-
rences in the BM of 13 to 50 % in early stage breast
cancer patients, and increases in patients with metasta-
tic breast cancer of up to 70 % [29]. In 2 of 29 non-
carcinoma control cases we found CK-ICC positive
DTCs in the BM. This f ind ing is not nove l .
Depending on the antibody used, CK-positive cells in
BM have been found in up to 5.5 % of individuals
without a known malignancy [29]. Therefore, it may
be questioned whether all disseminated epithelial cells
in the BM are truly malignant cells. Although earlier
characterization of these cells appeared to be difficult,
a malignant phenotype has been suggested [20, 30].
So, the option must be considered that these cells are
indeed tumor cells, but that these cells may not all
have the capacity to further metastasize. On the other
hand, it has recently been found in an experimental
model of colon cancer induced by male cancer cells
injected into female nude mice that disseminated ‘tu-
mor’ cells (i.e., epithelial-like cells) may be composed
of two different populations, one originating from the
cancer (cytokeratin-positive, Y chromosome-positive)
and one originating from the resident BM cells [31].
The clinical relevance of the molecular detection of
DTCs appears to be restricted by both tumor cell het-
erogeneities [32] and technical limitations. Genomic
analyses at a single cell level have shown that DTCs
detected with anti-cytokeratin antibodies frequently ex-
hibit heterogeneous tumor-specific aberrations, particu-
larly in patients without overt metastases [33]. Many
tumors are known to undergo an extended period of
‘dormancy’, but little is known about the mechanisms
underlying the ‘awakening’ of the dormant tumor cells,
which may ultimately lead to the formation of metasta-
ses. The steady state of dormancy may be disturbed by
changes in both DTCs and their surrounding microenvi-
ronment [33]. Tumor cells in the BM of CRC patients
may be in the Bwrong^ environment and, as such, be
kept in the dormant state [21]. Future efforts towards
Fig. 3 Kaplan-Meier overall survival curve for stroma-low and stroma-
high patients after surgery for primary colon cancer
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comprehensive genomic analysis of DTCs may provide
a deeper understanding of a clinically relevant biology
of DTCs [34].
For many years, tumor stromal formation or desmoplasia
was considered to be a passive bystander of tumorigenesis and
tumor progression. However, during the last 10 years, atten-
tion has shifted towards the tumor microenvironment and it is
now well established that tumor stroma plays an important
role in cancer initiation and progression. The tumor stroma
interacts with nonmalignant cells as well as with malignant
cells during different stages of tumorigenesis, ranging from
tumor onset to invasion and metastasis [35, 36]. TSR is a
relatively simple to apply and cheap cell-based parameter,
which is a strong quality. Multiple other studies have con-
firmed significant prognostic implications of the TSR not only
in colon cancer, but also in other solid tumors [37–42]. Further
research using a larger prospective cohort should bring this
parameter closer to implementation in the TNM classification
system.
5 Conclusions
DTCs were frequently detected in the BM of CRC patients,
but its presence (as based on CK-ICC) did not predict a worse
clinical outcome. In the future, a more precise molecular char-
acterization and functional analysis of DTCs in the BM may
provide a definite clue to its possible prognostic impact. In the
meantime, a pooled analysis of multi-institutional studies on
DTCs in the BM of CRC patients may provide more solid
information on its prognostic impact. We found that TSR
was associated with a worse overall survival in colon cancer
patients. Considering its simplicity and availability for con-
ventional clinical pathology, TSR may serve as a new prog-
nostic histological biomarker after its prognostic value has
been confirmed in a large prospective study.
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